Iobitridol 768mg/ml (Iodine 350mg/ml) infusion 500ml bags

AbstractObjectivesTo demonstrate non-inferiority of iobitridol 350 for coronary CT angiography (CTA) compared to higher iodine content contrast media regarding rate of patients evaluable for the presence of coronary artery stenoses.MethodsIn this multicentre trial, 452 patients were randomized to receive iobitridol 350, iopromide 370 or iomeprol 400 and underwent coronary CTA using CT systems with 64-detector rows or more. Two core lab readers assessed 18 coronary segments per patient regarding image quality (score 0 = non diagnostic to 4 = excellent quality), vascular attenuation, signal and contrast to noise ratio (SNR, CNR). Patients were considered evaluable if no segment had a score of 0.ResultsPer-patient, the rate of fully evaluable CT scans was 92.1, 95.4 and 94.6 % for iobitridol, iopromide and iomeprol, respectively. Non-inferiority of iobitridol over the best comparator was demonstrated with a 95 % CI of the difference of [-8.8 to 2.1], with a pre-specified non-inferiority margin of -10 %. Although average attenuation increased with higher iodine concentrations, average SNR and CNR did not differ between groups.ConclusionsWith current CT technology, iobitridol 350 mg iodine/ml is not inferior to contrast media with higher iodine concentrations in terms of image quality for coronary stenosis assessment.Key Points• Iodine concentration is an important parameter for image quality in coronary CTA. • Contrast enhancement must be balanced against the amount of iodine injected. • Iobitridol 350 is non-inferior compared to CM with higher iodine concentrations. • Higher attenuation with higher iodine concentrations, but no SNR or CNR differences.

Abstract licence: CC BY 4.0

To study the effect of non-ionic contrast media on anticoagulated and non-anticoagulated human whole blood samples, calorimetric measurements were performed. The anticoagulated plasma showed the greatest fall in the total ΔH after Iodixanol treatment. The plasma-free erythrocytes revealed a pronounced shift in the Tmax and a decrease in the ΔH of hemoglobin and transferrin. The total ΔH of Iodixanol treatment showed the highest decline, while Iomeprol and Iobitridol had fewer adverse effects. Similarly, the non-anticoagulated samples revealed a decrease both in the Tmax and the ΔH of albumin and immunoglobulin-specific transitions. The total ΔH showed that Iodixanol had more influence on the serum. The serum-free erythrocyte samples resulted in a significant drop in the Tmax of erythrocyte and transferrin (~5–6 °C). The ΔH of deconvolved hemoglobin and transferrin decreased considerably; however, the ΔH of albumin increased. Surprisingly, compared to Iomeprol and Iobitridol treatments, the total ΔH of Iodixanol was less pronounced in the non-anticoagulated erythrocyte samples. In sum, each non-ionic contrast medium affected the thermal stability of anticoagulated and non-anticoagulated erythrocyte proteins. Interestingly, Iodixanol treatment caused more significant effects. These findings suggest that conformational changes in blood components can occur, which can potentially lead to the increased prevalence of cardiovascular dysfunctions and blood clotting.

Abstract licence: CC BY 4.0

Abstract This study aimed to evaluate whether chemical exchange saturation transfer (CEST) imaging, in combination with the nonionic X-ray iodinated contrast agent Iobitridol, can detect extracellular pH (pHe) in rats with gliomas and enable the construction of quantitative pHe maps. CEST pH imaging was performed both on Iobitridol phantoms and on rat models bearing brain gliomas, using a 7.0 Tesla small animal MRI scanner (Agilent Technologies) and employing varying radiofrequency (RF) powers (1.5, 3.0, and 6.0 µT) based on the ratio of apparent exchange-dependent relaxation (AREXratio) technique (specifically, 1.5/6.0 µT and 3.0/6.0 µT). The results indicated that AREXratio can more effectively eliminate the influence of magnetization transfer (MT) effects from the CEST signal, thereby enabling more accurate quantification of pH. In vivo CEST pHe imaging distinctly delineated the glioma regions, and quantitative analysis demonstrated that the mean extracellular pH values within gliomas were closely aligned and exhibited an acidic profile. These results further verify the reliability and accuracy of CEST imaging for quantitative assessment of the tumor microenvironment’s acidity in gliomas. In conclusion, this study is the first to demonstrate that non-invasive CEST imaging can accurately detect the acidic extracellular microenvironment of brain gliomas and produce quantitative pHe maps with good spatial resolution, highlighting its significant potential for clinical translation.

Abstract licence: CC BY-NC-ND 4.0